| Understanding aberrant white matter development in schizophrenia: an avenue for therapy? | |
| | |
MedLine Citation:
|
PMID: 21721915 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Although historically gray matter changes have been the focus of neuropathological and neuroradiological studies in schizophrenia, in recent years an increasing body of research has implicated white matter structures and its constituent components (axons, their myelin sheaths and supporting oligodendrocytes). This article summarizes this body of literature, examining neuropathological, neurogenetic and neuroradiological evidence for white matter pathology in schizophrenia. We then look at the possible role that antipsychotic medication may play in these studies, examining both its role as a potential confounder in studies examining neuronal density and brain volume, but also the possible role that these medications may play in promoting myelination through their effects on oligodendrocytes. Finally, the role of potential novel therapies is discussed. |
| | |
Authors:
|
Mark Walterfang; Dennis Velakoulis; Thomas J Whitford; Christos Pantelis |
Related Documents
:
|
9929185 - Lifelines: using visualization to enhance navigation and analysis of patient records. 16766625 - Medical record versus researcher measures of height and weight. 15301175 - Can i see the medical records? 11722685 - What does the medical record reveal about functional status? a comparison of medical re... 7596605 - Legal implications for head and neck implants. 1604435 - Philosophy of medicine--from a medical perspective. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of neurotherapeutics Volume: 11 ISSN: 1744-8360 ISO Abbreviation: Expert Rev Neurother Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-07-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101129944 Medline TA: Expert Rev Neurother Country: England |
Other Details:
|
Languages: eng Pagination: 971-87 Citation Subset: IM |
Affiliation:
|
Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, Australia; Level 2, John Cade Building, Royal Melbourne Hospital 3050, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chronobiological therapy for mood disorders.
Next Document: Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?